- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05277675
Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study) (RANT)
A Prospective Study of Radiofrequency Ablation Combined With Systematic Neoadjuvant Therapy in the Treatment of Recurrent Hepatocellular Carcinoma
- To compare systemic neoadjuvant therapy (combination of immune checkpoint inhibitors and anti-angiogenic drugs (short for "targeted-immune therapy") combined with radiofrequency ablation (RFA) and RFA alone in the treatment of recurrent hepatocellular carcinoma(HCC) in 1-year recurrence-free survival (RFS) and overall survival (OS)
- To evaluate the clinical value of systemic neoadjuvant therapy (i.e. immune checkpoint inhibitors and targeted therapy) combined with RFA in the treatment of recurrent HCC, as well as the safety and efficacy of this strategy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
RFA is an important minimally invasive approach for recurrent HCC treatment, but is hampered by the high recurrence rate and limited ablation volume for the tumor. Therefore, the key to improving the efficacy of RFA is to maximize the complete ablation zone of tumor lesions and the killing of residual cancer cells. In recent years, due to the unique advantages of immune checkpoint inhibitors(ICIs), immunotherapy has gradually become a vital part of neoadjuvant therapy, and the scope of immunotherapy in malignant tumors expands. With administration of ICIs, revived tumor-specific CD8+ T cells proliferate and kill existing tumor cells and recirculate into the blood. After resection or ablation of the primary tumor, the remaining circulating tumor-specific CD8+ T cells and T cell clones present in the metastatic site can retain long-term anti-tumor immunity and play a vital role in continuous killing of residual cancer cells and immune surveillance. At present, the combination of targeted therapy and immune checkpoint inhibitors has achieved a higher objective response rate (ORR) and disease control rate (DCR) in the treatment of in treatment of HCC, which provides a reliable theoretical and practical basis for using as a strategy of neoadjuvant therapy.
The current reports on neoadjuvant therapy for HCC are limited to patients who are going undergo surgical resection, and there is no report on the neoadjuvant therapy prior to RFA. Since molecular targeted drugs generally have anti-angiogenic effects, drug withdrawal for two weeks or more (bevacizumab should be stopped for at least 4 weeks) before surgery is required to reduce the risk of intraoperative bleeding caused by targeted drugs and the hard-to-heal incision after operation. The longer-term drug withdrawal will prolong the preoperative waiting period, and the tumor may progress, leaving the patients loss of the opportunity for surgery. However, due to its advantage of minimal invasiveness, patients can undergo RFA directly without drug withdrawal.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kai Feng, MD,PhD
- Phone Number: +86-13228683383
- Email: fengkai7688@hotmail.com
Study Contact Backup
- Name: Kuansheng Ma, MD,PhD
- Phone Number: +86-15213249505
- Email: kuanshengma@outlook.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400038
- Recruiting
- Institute of hepatobiliary surgery,southwest hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Research subjects understand the research content and significance, and provide the written informed consent;
- age 18 - 75 years and gender is not limited;
- a history of liver resection or RFA for HCC which was clinically or pathologically diagnosed according to the standard of the American Association for the Study of Liver Diseases; the number of lesions ≤ 3, the largest lesion ≤ 3 cm, as demonstrated on by contrast enhanced CT/MRI;
- Patients who are unable or unwilling to undergo liver resection, and have not received other anti-tumor therapies before detection of the recurrence;
- Child Pugh A (≤ 7 points), no pleural ascites and hepatic encephalopathy requiring treatment; Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1;
- Within 7 days before enrollment, have sufficient liver and kidney function, suitable laboratory indicators (untreated): hemoglobin (HGB) ≥ 9.0 g/dl, neutrophils ≥ 1,500/mm3, PLT ≥ 50×109/L, serum ALB ≥ 28 g/L, TBIL < 50 umol/L, ALT, AST < 5 times the upper limit of normal, Bun, Cr < 1.5 times the upper limit of normal, INR < 1.7 or prolonged PT < 4 s;
- Consent to take the immune checkpoint inhibitor and molecular-targeted drugs;
- No other diseases affecting RFA treatment and targeted therapy combining with immune checkpoint inhibitors.
Exclusion Criteria:
- Patients who have a history of immune checkpoint inhibitor or targeted therapy;
- Tumor invades the branch or trunk of portal vein;
- Patients with extrahepatic metastasis;
- Patients who have an active autoimmune disease or a history of autoimmune disease, hyperthyroidism or hypothyroidism, asthma requiring bronchodilator treatment.
- Patients who have significant cardiovascular disease (heart failure grade Ⅲ or higher as defined by the New York Heart Association), myocardial infarction, unstable arrhythmia, unstable angina pectoris that occurred within 3 months before treatment;
- Patients who have a history of idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, or an evidence of active pneumonia during chest CT scan screening;
- Patients who have received allogeneic stem cell or solid organ transplantation (including liver transplantation);
- Patients who have taken any anti-tumor Chinese herbal medicine within 7 days before enrollment;
- Patients who have any other diseases, metabolic disorders, abnormal results of physical examination or laboratory tests, which may lead to contraindication to the use of the experimental drugs, or affect the reliability of the research results, or leave the patient at high risk of treatment complications, or affect patient compliance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neoadjuvant therapy+ RFA
After confirmation of HCC recurrence by imaging exam, subjects will receive neoadjuvant therapy (immune checkpoint inhibitors + targeted therapy) and then RFA
|
Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
|
Active Comparator: RFA alone
After confirmation of HCC recurrence by imaging exam, subjects will receive RFA treatment only.
|
RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year recurrence-free survival
Time Frame: 1 year after treatment
|
Evaluated by hepatic imaging examination (contrast-enhanced US/CT/MRI) at early stage combined with AFP and PIVKA-Ⅱtests.
|
1 year after treatment
|
1-year overall survival
Time Frame: 1 year after treatment
|
Evaluated by hepatic imaging examination (contrast-enhanced US/CT/MRI) at early stage combined with AFP and PIVKA-Ⅱtests.
|
1 year after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
procedure related complications
Time Frame: up to 1 year.
|
procedure related complications
|
up to 1 year.
|
immune-related adverse events
Time Frame: up to 1 year.
|
up to 1 year.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Recurrence
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Bevacizumab
- Lenvatinib
Other Study ID Numbers
- (A)KY2021083
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma Recurrent
-
Emory UniversityNational Cancer Institute (NCI); Eisai Co., Ltd.RecruitingUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
National Cancer Center, KoreaCompletedRecurrent Small Hepatocellular Carcinoma | Residual Small Hepatocellular CarcinomaKorea, Republic of
-
Ming ZhaoRecruitingRecurrent Hepatocellular CarcinomaChina
-
Sun Yat-sen UniversityRecruitingRecurrent Hepatocellular CarcinomaChina
-
Lion TCR Pte. Ltd.Third Affiliated Hospital, Sun Yat-Sen University; Agency for Science, Technology...UnknownRecurrent Hepatocellular CarcinomaChina
-
Sun Yat-sen UniversityCompletedRecurrent Hepatocellular Carcinoma
-
Xiaoshun HeLion TCR Pte. Ltd.UnknownRecurrent Hepatocellular CarcinomaChina
-
Eastern Hepatobiliary Surgery HospitalCompletedRecurrent Hepatocellular CarcinomaChina
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
-
China Medical University HospitalMinistry of Health and Welfare, TaiwanRecruiting
Clinical Trials on Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab
-
Peking Union Medical College HospitalHenan Cancer Hospital; Qilu Hospital of Shandong University; Beijing Tongren... and other collaboratorsRecruitingPrimary Central Nervous System LymphomaChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingResectable Hepatocellular Carcinoma
-
Guangxi Medical UniversityNot yet recruitingRecurrence | Hepatocellular Carcinoma | Immune Checkpoint InhibitorChina
-
Zhejiang Cancer HospitalRecruitingHepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | PharmorubicinChina
-
RenJi HospitalNot yet recruitingHepatocellular Carcinoma | Liver Transplant; Complications | Liver Cancer | Portal Vein Thrombosis | Radiotherapy; ComplicationsChina
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Sun Yat-sen UniversityRecruitingHepatocellular Carcinoma | PD-1 Inhibitor | Lenvatinib | Hepatic Arterial Infusion ChemotherapyChina
-
Tianjin Medical University Cancer Institute and...RecruitingPotentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder CancerChina
-
Guangxi Medical UniversityCompleted
-
Wen LiRecruitingUnresectable Hepatocellular CarcinomaChina